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HIGHLIGHTS

may be modified in animal models and patients.
• Epileptogenesis
of epilepsy is particularly feasible in tuberous sclerosis complex.
• Prevention
trials in TSC patients suggest vigabatrin may have antiepileptogenic effects.
• Clinical
• TSC mouse models indicate mTOR inhibitors have strong antiepileptogenic potential.
ARTICLE INFO
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Tuberous sclerosis complex (TSC) is an autosomal dominant neurocutaneous disorder affecting approximately 1
in 6,000 in general population and represents one of the most common genetic causes of epilepsy. Epilepsy
affects 90% of the patients and appears in the first 2 years of life in the majority of them. Early onset of epilepsy
in the first year of life is associated with high risk of cognitive decline and neuropsychiatric problems including
autism.
Recently TSC has been recognized as a model of genetic epilepsies. TSC is a genetic condition with known
dysregulated mTOR pathway and is increasingly viewed as a model for human epileptogenesis. Moreover, TSC is
characterized by a hyperactivation of mTOR (mammalian target of rapamycin) pathway, and mTOR activation
was showed to be implicated in epileptogenesis in many animal models and human epilepsies. Recently published studies documented positive effect of preventive or disease modifying treatment of epilepsy in infants with
high risk of epilepsy with significantly lower incidence of epilepsy and better cognitive outcome. Further studies
on preventive treatment of epilepsy in other genetic epilepsies of early childhood are considered.
This article is part of the special issue entitled ‘New Epilepsy Therapies for the 21st Century – From
Antiseizure Drugs to Prevention, Modification and Cure of Epilepsy’.

1. Introduction
Epilepsy is one of the few brain diseases known to man in which
people at risk may be identified, but there is no prophylactic treatment
to prevent the development of epilepsy in those at risk. The current
medical therapy for the majority of epilepsies aims to reduce the likelihood of seizure recurrence rather than to reverse the underlying cause

of the epilepsy. This approach results in seizure freedom only in about
two-thirds of the patients while 30% of patients suffer from drug-resistant seizures.
Unsatisfactory results of standard antiepileptic medication have led
researchers to the search for new therapeutic approaches and to novel
definitions of treatments: 1) disease modifying treatment, delivered to
patients after seizures, but based on the identification of the new genes

Abbreviations: AED, antiepileptic drug; EEG, electroencephalography; EOS, End of Study; FCD, focal cortical dysplasia; ILAE, International League Against Epilepsy;
MRI, magnetic resonance imaging; mTOR, mammalian target of rapamycin; NIH, National Institute of Health; SEGA, subependymal giant-cell astrocytoma; SWS,
Sturge-Weber syndrome; TSC, tuberous sclerosis complex
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maturation. In recent years many studies have appeared on biomarkers
of epileptogenesis, which should help in identification of proper candidates for preventive or disease modifying treatment (Auvin et al.,
2017; Pitkänen et al., 2019; Wu et al., 2016).
The first studies aimed at identifying infants with high probability
of epilepsy development have been reported in the latter part of the last
century. Lombroso (1983), Watanabe et al. (Watanabe et al., 1987,
1983) and Walther et al. (1987) documented a prognostic utility of
electroencephalography (EEG) for identification of infants with high
risk of infantile spasms. In the study of Walther et al. (1987) the authors
by the use of neonatal polygraphic EEG developed a compound score,
which predicted development of infantile spasms or hypsarrhythmia in
all 25 newborns with perinatal stress or brain malformation and positive scoring. It is important to note that they concluded: “The high
validity of the risk-score based on polygraphic tracing between conceptional age 36 and 44 weeks may allow pre-onset treatment preventing secondary mental deterioration due to hypsarrhythmia and
infantile spasms” (Walther et al., 1987).
However, the first use of preventive antiepileptogenic treatment
should be ascribed to Ville et al. (2002). The authors compared the
outcome of 21 children with Sturge-Weber syndrome (SWS) who were
treated following the first seizures with the outcome of 16 patients who
were treated preventively from the SWS diagnosis with phenobarbitone. Epilepsy was more frequent in those treated after seizures
(p < 0.01). They also presented earlier onset of seizures (p < 0.05) and
poorer cognitive outcome (Ville et al., 2002).

and precision medicine aimed to reduce seizure burden and its comorbidities by reversing or slowing the progression of the underlying
disease, and 2) antiepileptogenic treatment based on early identification of patients with high risk of epilepsy leading to sustained prevention of seizure development.
Epileptic encephalopathies of early childhood compose a specific
group of conditions characterized mostly by genetic origin, early presentation of seizures and their strong impact on cognitive development.
Early diagnosis of the underlying disease may allow therapeutic intervention before clinical seizures, ideally reducing the risk of epilepsy and
avoiding unnecessary epileptic comorbidities.
In this review we will describe a current status of knowledge regarding the use of an antiepileptogenic approach in one of epileptic
encephalopathies - tuberous sclerosis complex (TSC). The NIH
Workshop on Antiepileptogenic therapy and Disease modification held
in Washington in 2018 considered TSC as one of the most appropriate
conditions for developing this kind of therapy.
2. Concept of epilepsy modification and first clinical applications
In 1881 Gowers (1881) first noted that there is often a seizure-free
period lasting several months to years between brain insults and the
onset of symptomatic epilepsy. This interval, between brain injury and
appearance of clinically obvious seizures, called the “latent period of
epileptogenesis”, defines a cascade of changes that occur in the brain
after an injury that lead to the first clinical seizure. Epileptogenesis
itself is a process of structural and functional changes transforming the
normal brain to one that can generate abnormal neuronal activity that
subserves seizures. Moreover, the process of epileptogenesis does not
end with the first seizure, but extends further to include progression of
the disease, development of drug-resistant epilepsy, etc. (Pitkänen and
Engel, 2014).
So far the “gold standard” of epilepsy treatment has been treatment
after clinical seizures. However, animal studies indicated that pharmacological intervention during a latent period of epileptogenesis in
pre-defined cohorts of animals may delay or halt the appearance of
seizures (Blumenfeld et al., 2008; Yan et al., 2005; Zeng et al., 2008).
The latent period may offer a window of opportunity in which an appropriate treatment may stop or modify the epileptogenic process induced by a brain insult (Stafstrom et al., 2011) (Fig. 1).
On the basis of this concept, several clinical trials have been performed to assess whether pre-seizure administration of an antiepileptic
drug (AED) prevents the development of epilepsy after head trauma.
These studies with the use of conventional AEDs, such as phenytoin,
phenobarbital, carbamazepine, or valproate have failed to prevent
epileptogenesis (Temkin, 2009, 2001), giving a rise to the concept that
a true “antiepileptogenic drug” should have mechanisms of action
distinct from traditional AEDs. However there are additional factors,
which may be responsible for lack of preventive effect in this trials.
Besides severity and location of brain injury or gap between an injury
and onset of treatment, there are other factors which may contribute to
the effect of therapeutic intervention, such as age of patient and brain

3. TSC as a model for epilepsy modification
Early childhood epilepsies, especially of genetic origin, seem to represent a particularly suitable group for preventive/disease modification studies. They have homogenous cause of epilepsy (one disease),
early and predictable age of epilepsy presentation and lesser number of
epileptogenic factors, which may contribute to the process of epileptogenesis, compared with the older population. TSC due to its epilepsy characteristics may be considered as particularly good candidate
for such studies due to several reasons: 1/unlike many other conditions
predisposing to epilepsy, patients can be diagnosed with TSC prior to
onset of epilepsy due to non-neurological findings (cardiac rhabdomyomas, skin lesions and positive family history) allowing early intervention, 2/high risk and prevalence of epilepsy and 3/known pathophysiological mechanisms of the disease that can be targeted with
preventive treatment.
3.1. Epilepsy characteristics in TSC
TSC is an autosomal dominant disease that affects approximately 1
in 6,000 individuals and is a common genetic cause of early childhood
epilepsy. Patients with TSC carry loss-of-function germline mutations in
either of the tumor suppressor genes TSC1 or TSC2. The TSC protein
complex, composed of these genes products (hamartin and tuberin respectively), inhibits the mechanistic target of rapamycin (mTOR)

Fig. 1. Concept of epileptogenesis and different treatment approaches in TSC.
2
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pathway (Henske et al., 2016).
Epilepsy appears in about 90% of TSC patients during their lifespan.
Approximately 65% of those with epilepsy have medically refractory
epilepsy, which in turn increases the likelihood of co-morbid developmental delay and autism. In a prospective study of infants followed
from the neonatal period to two years of life, 71% of children developed
epilepsy (Jóźwiak et al., 2011). In a large group of patients followed at
The Children's Memorial Health Institute in Warsaw by video EEG
(carried out every 4 weeks in the first 6 month of life) most patients had
normal EEG in the first 2 months of life. In the next few months about
70% of patients developed spike and wave complexes or polyspike
activity on EEG, which, if not treated, evolved to more generalized
activity. First, short-lasting focal seizures could be seen in children with
multifocal spikes or spike and wave complexes, mostly in the 4th or 5th
month of life (Domańska-Pakieła et al., 2014). If not successfully
treated, they transform to more generalized type of seizures - infantile
spasms.
In about 5–6% of children with TSC, the first seizures appear in the
neonatal period. In 11 out of 21 (52.4%) patients with neonatal seizures
reported by Kotulska et al. (2014) brain MRI revealed large malformations of cerebral cortex, meeting the criteria for focal cortical
dysplasia (FCD). Other risk factors for neonatal epilepsy included:
perinatal complications and congenital SEGAs. Presence of FCD was
associated with more severe epilepsy and worse neuropsychological
outcome.

abnormalities within tubers and the perituberal region, or potentially
completely independent of tubers, that are likely mTOR-dependent and
could contribute to epileptogenesis in TSC. For example, in human TSC
tuber specimens or animal models, abnormalities in ion channel or
neurotransmitter receptor expression, synaptic plasticity, astrocyte
glutamate transport, astrogliosis, neuronal cytomegaly, hypomyelination, microglia activation, and inflammatory mechanisms have been
identified (Carson et al., 2012; Goto et al., 2011; Meikle et al., 2007;
Sosunov et al., 2008; Uhlmann et al., 2002; Zhang et al., 2015). Many of
these abnormalities have been shown to be reversed by mTOR inhibitors, at least in animal models (see below). There may also be a link
between GABAergic modulation and the mTOR pathway, as vigabatrin
may also inhibit mTOR activity (Zhang et al., 2013).
In addition to TSC, there is now evidence that mTOR is dysregulated
in other types or causes of epilepsy. In patients, this is most clear in
related types of cortical malformations, such as focal cortical dysplasia
type IIb and hemimegalencephaly, where somatic or germline mutations have been identified in upstream regulators of the mTOR
pathway, such as DEPDC5, PI3K, PTEN, and mTOR itself (Iffland and
Crino, 2017).
In some of these cases, there is evidence that these mutations lead to
hyperactivation of the mTOR pathway, similar to TSC, suggesting that
mTOR inhibitors may be rational treatments for epilepsy associated
with these cortical malformations. Furthermore, mTOR activation has
been shown to occur in animal models of acquired epilepsy, such as
following traumatic brain injury, neonatal hypoxia, or kainate-induced
status epilepticus (Guo et al., 2013; Talos et al., 2012; Zeng et al.,
2009). mTOR activation leads to mossy fiber sprouting, neuronal death,
and neurogenesis, which are associated with and may promote epileptogenesis in these models.

3.2. Role of mTOR activation in epileptogenesis in TSC and other epilepsies
Prevention or disease modification of epilepsy depends on understanding the underlying mechanisms of epileptogenesis which can then
be targeted with early therapeutic intervention. Supporting TSC as a
model for epilepsy modification, critical mechanisms of epileptogenesis
have started to be identified in TSC, particularly related to the mechanistic target of rapamycin (mTOR) pathway (Wong, 2013). mTOR is
a relatively ubiquitous protein kinase involved in a number of important molecular and cellular functions throughout the body, including cellular growth, proliferation, and protein synthesis (Lipton and
Sahin, 2014; Saxton and Sabatini, 2017). The two TSC genes, TSC1 and
TSC2, normally inhibit mTOR and thus limit excessive cellular growth
and proliferation. In TSC, mutation of either TSC1 or TSC2 leads to a
disinhibition or hyperactivation of the mTOR pathway, which then
causes excessive cellular growth and proliferation, promoting tumor
formation and progression in various organs that is characteristic of
TSC. Clinical trials have found that mTOR inhibitors, such as rapamycin
and everolimus, represent an effective treatment for brain subependymal giant cell astrocytomas, renal angiomyolipomas, and pulmonary lymphangioleiomyomatosis (Franz, 2013; Krueger et al., 2010),
leading to official approval of mTOR inhibitors for these oncological
indications in TSC.
Compared with tumor growth, the role of mTOR in the brain in
causing epileptogenesis is more complex, but mTOR has been implicated in a number of cellular and molecular processes in the brain
that directly affect neuronal excitability and seizures (Wong, 2013).
Epilepsy in TSC is generally not directly related to tumor growth per se,
but is strongly linked to tubers, as surgical removal of tubers can
sometimes eliminate seizures in some TSC patients (Kaczorowska et al.,
2011; Ma et al., 2012; Ostrowsky-Coste et al., 2019). Patients with large
tubers, as well as tubers hypointense on T1weighted, hyperintense on
T2 weighted and heterogeneous on FLAIR images, were more likely
reported to have severe epilepsy than patients with other types of tubers (Pascual-Castroviejo et al., 2013). Neuropathological examination
of surgically removed cortical tumors from TSC patients revealed features characteristic for FCD type IIb: dysmorphic neurons and balloon
cells together with disruption of cortical lamination (Grajkowska et al.,
2008; Yasin et al., 2010).
There are a number of pathological, cellular, and molecular

4. Clinical trials of epilepsy modification in TSC
4.1. Trials in animal models
The increase in mTOR activity and its association with epilepsy in
TSC suggest that mTOR inhibitors may be a rational treatment for
epilepsy modification in TSC, including possible prevention of epilepsy
1
(Sadowski et al., 2015). The effects of mTOR inhibitors, typically rapamycin, on seizures have been tested in multiple animal models of TSC
and related mTORopathies (Goto et al., 2011; Ljungberg et al., 2009;
Meikle et al., 2008; Zeng et al., 2008). The timing of treatment can be
modified to investigate potential early preventive or disease-modifying
effects versus late conventional antiseizure/antiepileptic effects. In
some cases, late rapamycin treatment of TSC knockout mice with established epilepsy has been shown to decrease existing seizures, consistent with a disease-modifying effect or traditional antiseizure effect.
In addition, when initiated prior to the onset of epilepsy, rapamycin has
also been shown to prevent the onset of epilepsy, compared with untreated or vehicle-treated mice. For example, in conditional knockout
mice involving inactivation of the TSC1 gene in astrocytes and neurons,
rapamycin initiated at two weeks of age inhibited mTOR activity and
completely prevented epilepsy from occurring in all treated mice,
whereas 100% of vehicle-treated mice develop seizures by 4–6 weeks of
age (Zeng et al., 2008). Importantly, rapamycin also prevented the
underlying pathological, cellular, and molecular mechanisms that cause
epileptogenesis, such as megalencephaly, astrogliosis, and impaired
glutamate transporter expression, suggesting that these effects of rapamycin were consistent with true preventive or disease-modifying
actions, not simply a suppression of seizures. However, it should be
noted that once rapamycin was stopped, the pathological and cellular
phenotype and seizures could emerge as mTOR activity rebounded,
suggesting that continued treatment may be necessary to maintain a
1

3
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long-term effect. This temporal requirement could be more a function of
the relatively simplistic, reductionist animal models, as human brain
development may involve more intricate, complex developmental
windows or critical periods, after which chronic treatment may not be
necessary.
The preclinical data supporting efficacy of mTOR inhibitors in
treatment of epilepsy in TSC, including prevention and disease-modification, are consistent and compelling. Animal models of TSC similarly
provide the opportunity to investigate potential alternative therapies
for epilepsy modification. Other therapeutic approaches could target
mechanisms related to or downstream from the mTOR pathway or
could be completely independent of mTOR. Vigabatrin, which is already a very effective, established treatment for infantile spasms in
TSC, potentially represents a unique approach to epilepsy modification
in TSC from a mechanistic standpoint. The established mechanism of
action of vigabatrin involves increasing GABA levels in the brain via
inhibition of its breakdown by GABA transaminase. However, other
GABA potentiating drugs, such as benzodiazepines and barbituates, are
not as effective as vigabatrin against infantile spasms in TSC, suggesting
that vigabatrin may have another mechanism of action specific to TSC.
Toward this end vigabatrin has also been found in mouse models of TSC
to have some effects in inhibiting mTOR, as reflected by inhibition of
phosphorylation of the downstream mTOR effector, S6 protein. (Zhang
et al., 2013). These dual, combined actions might account for vigabatrin's strong efficacy for infantile spasms in TSC and support its application for potential prevention and disease-modification of epilepsy, as
currently being pursued in clinical trials in TSC patients.

In TSC, the diagnosis of the disease is being increasingly made before seizures (Słowińska et al., 2018) enabling monitoring of EEG
changes and identification of patients at high risk of developing epilepsy 3(Bernardo et al., 2018; Domańska-Pakieła et al., 2014; Wu et al.,
2016).
A longitudinal study was recently completed which focused on interictal scalp epileptiform discharges and was able to identify impending epilepsy in the majority (77%) of seizure-naïve TSC infants. In
this longitudinal cohort TSC infant study participants were enrolled
across 5 TSC centres for a total of 40 infants with a mean age of 82.4
days, and 32 completed the 24 month study. Two were lost to follow up
and 6 were treated with AED either due to electrographic seizures and/
or epileptiform discharges on their EEGs prior to the onset of clinical
seizures. Seventeen of the 32 remaining children developed epilepsy at
a mean age of 7.5 months (SD = 4.4). Generalized/focal slowing,
hypsarrhythmia, and generalized/focal attenuation were not predictive
for the development of clinical seizures. Presence of inter-ictal epileptiform discharges had a 77.3% positive predictive value and absence
a 70% negative predictive value for developing seizures by 2 years of
age. Epileptiform discharges preceded clinical seizure onset by 3.6
months (mean). The results of this study supports the use of a 1 h awake
and asleep EEG as a biomarker for ongoing epileptogenesis in most but
not all infants with TSC(Wu et al., 2019, 2016).
Our data suggest there is a specific association between severity of
epilepsy and co-morbid conditions, including developmental delay,
reported previously in retrospective and prospective series (Capal et al.,
2017; Chu-Shore et al., 2010; Davis et al., 2017; Northrup et al., 2013).
This study showed significant decline only in infants with ongoing
seizures, but not in those who did not developed seizures or whose
seizures came under control. There is emerging evidence that persistent
seizures, but not so history of interictal epileptiform activity, nor history of well controlled seizures, correlated with low scores on the Vineland and Mullen tests at 2 years of age (Wu et al., 2016).
The results of these observational studies allowed studies with active preventive use of vigabatrin in TSC infants. An open-label study of
preventive treatment in infants with TSC (Jóźwiak et al., 2011) demonstrated that in patients with paroxysmal discharges on EEG it is
possible to modify the outcome of the disease by antiepileptic treatment
before the onset of clinical seizures with vigabatrin, a drug standardly
used to treat infantile spasms in TSC. Preventive vigabatrin treatment
used in a group of 11 TSC infants with EEG changes improved the
outcome when compared to a historical control group of 31 infants in
whom neither EEG monitoring, nor prevention were introduced. Infants
were followed up to the age of 24 months. Preventive treatment increased the proportion of seizure free patients (93% versus 35% in a
standard treatment group), lowered the risk of drug resistant epilepsy
(7% versus 42%) and the risk of intellectual disability (48% vs 14%;
p = 0.031; mean IQ score 68.7 vs 92.3; p < 0.05) (Jóźwiak et al.,
2011)4. On longer follow-up, at median age of 8.8 years of age, only 5
of 14 (35.7%) required antiepileptic treatment and in 6 subjects we
were able to withdraw the treatment completely. Patients with the
preventive treatment had much better neurocognitive outcome (IQ
score of 81.6 in comparison to 52.8 in an age-matched group receiving
standard treatment (p < 0.03 (Jóźwiak et al., 2019; Jóźwiak and
Kotulska, 2014). The most important caveats about this study were the
small number of the patient and open-label, single arm design with a
historical control group; thus larger, prospective controlled randomized
trials have been recommended.
The EPISTOP project (Clinical- Trials.gov Identifier NCT02098759),
a large collaborative study funded by European Union within 7th Frame
Programme to examine the risk factors and biomarkers of epilepsy has
addressed this issue. In the clinical part of the project, a clinical trial

4.2. Trials in humans
4.2.1. Early or pre-seizure treatment with conventional drugs
Currently, treatment of epilepsy is usually introduced after the
clinical diagnosis of epilepsy is set. According to the newest
International League Against Epilepsy (ILAE) classification of epilepsies
released in 2017, epilepsy is diagnosed when an individual had at least
2 unprovoked seizures >24 h apart, or one unprovoked seizure and at
least 60% risk of having another seizure over next 10 years. All available pharmacological treatments of epilepsy are actually only seizure
suppressing, or ‘antiepileptic’ and none are disease-modifying, or ‘antiepileptogenic, when introduced after clinical seizures. Preclinical
models have showed that some antiepileptic drugs, however, may
prevent or alleviate epilepsy when given before seizures (Blumenfeld
et al., 2008; Yan et al., 2005). In humans, the trials to prevent epileptogenesis using standard antiepileptic drugs after severe traumatic
brain injury (Bakr and Belli, 2018; Mani et al., 2011; Wat et al., 2019),
stroke (Angriman et al., 2019), or craniotomy (Greenhalgh et al., 2018;
Lee et al., 2018) have been performed and were unsuccessful. The
failure of anti-epileptogenic effects in these studies may in part result
from inclusion of patients at different risk of epilepsy, highlighting the
need for reliable and clinically applicable biomarkers of epileptogenesis.
Up until now, the only clinically available tool to detect epilepsy
development before clinical seizures is a change in EEG pattern. An
increasing body of evidence indicates that the spikes on EEG precede
clinical seizures during epileptogenesis in various clinical conditions
(Bernardo et al., 2018; Chang et al., 2012; Chauvière et al., 2012; van
Rooij et al., 2010; Wu et al., 2016). In the study reported by van Rooij
et al. 2(van Rooij et al., 2010), infants with severe hypoxic-ischemic
encephalopathy were included and monitored by EEG. Antiepileptic
treatment with phenobarbitone was randomly assigned in infants either
before or after the onset of clinical seizures. The results suggested that
epilepsy was less severe in infants treated preventively, but differences
were not significant, probably due to the small study population.

3
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comparing preventive and standard antiepileptic treatments has been
carried out. Ninety-seven infants with definite TSC were included and
followed from birth up to the age of 24 months with serial EEG, imaging, and laboratory tests. In the randomized part of the study, children
were randomly assigned to either preventive or standard antiepileptic
treatment with vigabatrin. Preventive treatment was introduced after
the onset of spikes on EEG but prior to seizures. The results of the study
are currently in preparation.
Similar randomized controlled double blind clinical trial in TSC
infants, has been recently launched also in the US as the PREVeNT trial
(PReventing Epilepsy Using Vigabatrin In Infants with Tuberous
Sclerosis Complex; (Clinical- Trials.gov Identifier NCT02849457). The
study is currently underway in the United States. The results of this
study will provide important information which will determine if early
interventions prior to the development of epilepsy with antiseizure
medications such as vigabatrin will be useful to prevent epilepsy, the
development of refractory epilepsy and cognitive impairment in children with epileptiform EEGs. Perhaps as or more important than epilepsy outcomes in the TSC patient population, is their developmental
outcome and risk for autism. The PREVeNT study begins to answer the
role of preventive antiepileptic therapy in infants with TSC and how
targeting epilepsy prevention impacts developmental outcomes for
these patients.

2018), a broad range of antiepileptic drugs is used in attempts to
achieve seizure control, including: vigabatrin, valproic acid, levetiracetam, carbamazepine, oxcarbazepine, topiramate, phenytoin, mTOR
inhibitors, and others (Overwater et al., 2015). According to he data
from the TSC Natural History Database which included 1328 TSC individuals from the U.S. and Europe, 83.6% of patients with TSC have
epilepsy (Song et al., 2018). Nearly all patients with TSC and epilepsy
receive medical treatment, and in 64.5% of them 3 or more antiepileptic drugs are required. Other treatment options for epilepsy included epilepsy surgery in 25.3%, dietary treatment in 7.9%, and
mTOR inhibitors in 1% of the patients (Song et al., 2018). It should be
noted that the data in the database were captured between 2006 and
2014 and currently the use of mTOR inhibitors for epilepsy associated
with TSC is likely more common.
In TSC, epilepsy usually presents within the first months of life.
Another recent study based on a large multicenter registry of over 2.000
patients showed that nearly 80% of children with TSC developed epilepsy before the age of 2 years (Nabbout et al., 2019). It is established
that timing of treatment initiation is crucial for epilepsy outcome in TSC
(Canevini et al., 2018). In a study of Cusmai et al. (2011),5 all children
with TSC who received antiepileptic treatment later than one week
after the first clinical seizure had intellectual disability and more than
60% of them had drug-resistant seizures. When antiepileptic treatment
was introduced within first week after the onset of clinical seizures, the
risk of intellectual disability and drug-resistant seizures decreased by
about 30%–60% (Cusmai et al., 2011; Jóźwiak et al., 2011).
In infants, focal seizures are frequently followed by infantile spasms.
Their incidence was reported to be as high as 70% in some older studies
and decreased significantly with an introduction of EEG surveillance
(Chu-Shore et al., 2010; Curatolo et al., 2001; Overwater et al., 2015).
Vigabatrin is widely used for infantile spasms and focal seizures in infants (Curatolo et al., 2018; Overwater et al., 2015). In recent years, an
increasing body of evidence indicates that vigabatrin might be also
effective in epileptic spasms and tonic seizures in older patients with
TSC (van der Poest Clement et al., 2018). It has been also shown that
high dose of vigabatrin prevents the relapse of infantile spasms
(Hussain et al., 2018), suggesting that it may change the natural course
of epilepsy in TSC. Vigabatrin has been used in three epilepsy ion studies in infants with TSC: the open-label study published by Jozwiak
et al., in 2011, as well as two randomized trials: EPISTOP and PREVeNT
studies (Table 1).
Both timing of treatment initiation and the use of appropriate
medication are addressed in current recommendations for the management of epilepsy in TSC. New European recommendations have
been published in 2018 by the group of experts in TSC (Curatolo et al.,
2018). The need for early diagnosis and presymptomatic assessment for
epilepsy with EEG surveillance in newborns and infants with TSC has
been highlighted. Video EEG recording is recommended in every newly
diagnosed newborn and infant and follow-up video EEG recording
should be performed every 4 weeks until the age of 6 months and every
6–8 weeks thereafter in infants unless seizures are disclosed. Treatment
with vigabatrin should be initiated immediately after electrographic or
clinical seizures, whichever first, are recognized (Curatolo et al., 2018).
Vigabatrin is the first choice treatment for focal seizures 6and infantile
spasms in TSC. The recommended dose is 100–150 mg/kg as lower
dosage is associated with higher rate of seizure recurrences (Hussain
et al., 2018).
In non-responders, second antiepileptic drug should be selected
considering the age of the patient and seizure type. Epilepsy surgery is
recommended to be considered early, after the failure of second antiepileptic drug. In patients with few tubers and good anatomic-electro-

4.2.2. Trials with mTOR inhibitors
While controlled preventive clinical trials of vigabatrin for epilepsy
in TSC are ongoing, comparable preventive clinical trials of mTOR inhibitors are still under development. However, the mTOR inhibitor,
everolimus, has been tested rigorously in clinical trials for conventional
antiseizure effects in TSC patients with drug-resistant epilepsy. Initial
suggestion for a potential effect of everolimus against seizures in TSC
patients was derived from the clinical trials of everolimus for tumors in
patients who had concurrent epilepsy (Kotulska et al., 2013; Krueger
et al., 2010). Open-label drug studies further supported that everolimus
decreased seizure frequency in TSC patients, independent of treatment
of tumors (Krueger et al., 2013; Sadowski et al., 2016). Most definitively, a recent double-blind, randomized, placebo-controlled trial
(EXIST-3) showed that everolimus was significantly more effective than
placebo in reducing focal seizures in TSC patients with drug-resistant
epilepsy (French et al., 2016). A high exposure everolimus group had a
median reduction in seizure frequency of 40% compared with 15% in
the placebo group. Longer term follow-up of this study indicates that
everolimus has a sustained effect on seizure frequency (Franz et al.,
2018).
Given the precedent of preventive clinical trials with vigabatrin for
epilepsy in TSC, similar preventive trials with mTOR inhibitors are in
the planning stages, but have not yet been conducted. One barrier to
progress has been the concern for potential adverse effects of mTOR
inhibitors in young infants, given the role of the mTOR pathway in
normal growth and development. In a large multicenter survey of 45
children below 2 years of age severe adverse events (Grade 3) were
present in 7 (16%) subjects and no life-threatening (Grade 4) or death/
disability (Grade 5) were reported. Treatment was discontinued due to
adverse events in 9 of 45 (20%) (Krueger et al., 2018). Nevertheless,
adverse events were mild to moderate in the majority of cases and
overall mTOR inhibitors were well-tolerated in this patient population,
suggesting that a preventive clinical trial of mTOR inhibitors for epilepsy is feasible and safe.
5. Current recommendations and clinical practice
Current treatment practices for epilepsy in TSC include medical
treatment of seizures, ACTH, epilepsy surgery, ketogenic diet and its
variants, vagus nerve stimulation, and, recently, preventive strategies
in infants. Given that epilepsy in TSC is frequently resistant to medical
treatment (Chu-Shore et al., 2010; Nabbout et al., 2019; Song et al.,
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Table 1
Comparison of EPISTOP and PREVeNT trials with preventive epilepsy treatment in TSC. EEG = electroencephalography; EOS = end of study; WES = whole genome
sequencing.

Trial type
Enrolment goal
Randomization
Intervals between EEGs
Study design
Blood biomarkers
Genetic testing
Developmental testing
Autism evaluation

EPISTOP

PREVeNT

IIb/III
N = 100 (101 enrolled)
Based on presence of epileptiform activity; blinded; 1:1; Vigabatrin vs
no treatment
4 weeks in the first 6 mo, 6 weeks in 7–12 mo,8 in 13–24 mo
24 mo follow up, Study end points: time to first seizure, risk of drug
resistant epilepsy, proportion of patients with seizures
Serial blood collection (at enrolment, at abnormal EEG, at seizures, at
EOS), Biomarkers analysed in the project
WGS within the project
6, 12, 18, 24 mo
6, 12, 24 mo

IIb
N = 80
Based on presence of epileptiform activity; blinded; 1:1; Vigabatrin vs placebo

clinical correlations the surgical treatment results in 50–60% chance of
long-term seizure freedom (Ostrowsky-Coste et al., 2019). In patients
with a significant “tuber burden” long-term monitoring and multiple
neuroimaging and electrographic source localization procedures must
be applied (Jansen et al., 2007). Restricted availability of highly specialized epilepsy surgery centres for such patients may be a limitation of
this method.
Ketogenic diet is an important treatment option in cases of medically intractable epilepsy related to TSC especially given the mechanism
of action of ketogenic diet in regulating epigenetic mechanisms and the
mTOR pathway (Boison, 2017; McDaniel et al., 2011). According to
Park et al. (2017) up to 80% of TSC patients with drug-resistant epilepsy may experience at least 50% reduction of seizures number.
There is an increasing interest in the use of mTOR inhibitors as a
first antiepileptogenic treatment in TSC infants. Currently licensed
mTOR inhibitor for epilepsy in TSC is registered after 12 months of age
while such preventive treatment should be applied in the first months of
life. However there is increasing number of reports on the use of mTOR
inhibitors in young infants documenting that such treatment may be
safe and effective (Curatolo et al., 2016a, 2016b; Curatolo and Maria,
2013; Jóźwiak et al., 2016; Kotulska et al., 2013; Krueger et al., 2018).
As TSC represents a genetic encephalopathy, where encephalopathy is
caused not only by epilepsy per se, but also by underlying genetic
mutation and its molecular consequences, there are increasing expectations that the treatment with mTOR inhibitors may be more efficient and holistic in infants with TSC.
The U.S. recommendations of the 2012 International Tuberous
Sclerosis Complex Consensus Conference highlighted the need for
education of the parents and caregivers to recognize focal seizures as
well as infantile spasms (Krueger et al., 2013). All children who received TSC diagnosis should undergo a baseline EEG. If no clinical
seizures were recognized or reported and baseline EEG is abnormal, it
should be followed with 24-hour video EEG in order to disclose electrographic or subtle clinical seizures (7Krueger et al., 2013).

Samples stored in TSC repository
6, 12, 24, 36mo,
24 and 36 mo

an incidence of epilepsy over 60% in the first year of life, well recognized natural course of the disease, and established severe epilepsy
comorbidities should be considered as a potential candidates for preventive treatment (Jóźwiak and Kotulska, 2014). In these conditions
early therapeutic intervention may prevent, delay or ameliorate the
development of epilepsy, drug-resistant epilepsy and intellectual disability and significantly improve the quality of life of young patients
and their families.
There is an increasing number of papers demonstrating the utility of
pre-seizure EEG surveillance in early diagnosis of TSC as a first step to
preventive treatment (Benova et al., 2018; Chung et al., 2017; Whitney
et al., 2017). Studies in SWS are in the pipeline (Pinto et al., 2016). The
recent clinical trials in TSC indicate that a preventive treatment for
epilepsy in TSC is feasible and could become standard of care in the
near future.
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